Should Star Athletes Get the COVID Vaccine Early?
Sports teams have faced intense blowback since the spring over the perception that they have received special treatment in a pandemic. Now some public health experts are weighing a counterintuitive idea for how they could help end it.
December 6, 2020 — Wall Street Journal
Most COVID-19 Vaccines Won’t Affect HIV Risk: Here’s What the Science Tells Us
We can now see a light at the end of the COVID-19 tunnel, thanks to a growing amount of positive news on vaccines in development. There are many COVID-19 vaccines in the pipeline, and most—including the three that are currently the farthest along in development (one by Moderna, one by PFizer/BioNTech, and one by AstraZeneca/Oxford)—do not present any concern when it comes to potential HIV risk.
December 2, 2020 — The Body
Tortoise and the Hare: Why a COVID Vaccine Is Outrunning Its HIV Counterpart
Four COVID jabs’ efficacy results have been released within less than a year after the trials had started. But this is far from the norm. Researchers have been working on HIV vaccines for over three decades — and we still don’t have one. Here’s why.
December 1, 2020 — Bhekisisa
The Case for an HIV Cure and How to Get There
We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
November 30, 2020 — Lancet HIV
The Long Darkness Before Dawn
Each week, good news about vaccines or antibody treatments surfaces, offering hope that an end to the pandemic is at hand. And yet this holiday season presents a grim reckoning. The United States has reached an appalling milestone: more than one million new coronavirus cases every week. Hospitals in some states are full to bursting. The number of deaths is rising and seems on track to easily surpass the 2,200-a-day average in the spring, when the pandemic was concentrated in the New York metropolitan area.
November 30, 2020 — New York Times
‘Your Life Is Altered, but It’s Not the End’: Life With HIV, Stigma and Discrimination
The dark days of the HIV pandemic are over, but patients still face social stigma and emotional distress that can push them to stop treatment or even into a deep depression. Hear it first-hand from people who’ve experienced it.
November 30, 2020 — Bhekisisa
Multi-Stakeholder Consensus on a Target Product Profile for an HIV Cure
Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy.
November 30, 2020 — Lancet HIV
U=U: We Should Put People Living With HIV at the Centre of HIV Prevention Efforts
The message is simple to understand. An undetectable viral load in people living with HIV equals an untransmissible virus. The success of this concept, however, depends on strict adherence to antiretroviral therapy (ART).
November 24, 2020 — Spotlight
Opinion: Why Exciting Results From Vaccine Research Are Just the Beginning of Efforts to End COVID-19
The news last week and again this week that at least two highly effective vaccines may be on the horizon is a welcome respite from the devastating impact of COVID-19 on global health. In under a year, SARS-CoV-2 has already caused more than 56 million infections and 1.3 million deaths.
November 19, 2020 — Devex
Six Injections a Year Could Stop New HIV Infections
Six shots a year of an antiretroviral (ARV) drug can protect women from contracting HIV, new research shows. Activists say although the jab won’t be available immediately, countries need to start doing the planning—and the math—to introduce the bimonthly injection now.
November 16, 2020 — Mail & Guardian
Study Finds Long-Acting Shot Helps Women Avoid HIV Infection
Researchers are stopping a study early after finding that a shot of an experimental medicine every two months worked better than daily pills to help keep women from catching HIV from an infected sex partner.
November 9, 2020 — Washington Post
The World Could See a COVID-19 Vaccine by Next Year — Here’s Who Will Get It and How
Even if a jab is shown to work, there won’t be enough doses for everyone. Countries such as South Africa would need to make tough decisions about who it would give the vaccine to — and more importantly how to create a system to get it to them.
October 14, 2020 — Bhekisisa
Invest More in HIV Prevention, Experts Tell FG
Experts have called on the federal government and other stakeholders to invest more in efforts to prevent HIV infection human immunodeficiency virus, HIV prevention interventions while advocating for supportive policy and programmes.
October 13, 2020 — Vanguard
HIV/AIDS Prevention: NGOs Urge FG to Leverage Pop Culture to Reach Youths
A coalition of NGOS on Monday urged the Federal Government to utilise diverse popular culture (pop culture) as avenues to create awareness and sensitise youths on HIV/AIDS prevention. The NGOs made the call during an online discussion on the role of media in HIV prevention advocacy’’, organised by the AVAC in collaboration with Journalists Against AIDS Nigeria (JAAIDS).
October 6, 2020 — The Guardian Nigeria
Science, Not Politics, Must Lead to COVID Vaccine Approvals
COVID-19 has devastated communities and health systems around the world — but it has also created an historic global effort leading to the unprecedented development of more than 165 potential vaccines against COVID-19. Equally impressive innovations are speeding vaccine testing within a rigorous scientific framework, while manufacturing and transportation capacity are being scaled up to distribute millions of doses of future COVID vaccines to those who need them most.
September 30, 2020 — POZ
Science, Not Politics, Must Lead to COVID Vaccine Approvals
COVID-19 has devastated communities and health systems around the world – but it has also created an historic global effort leading to the unprecedented development of more than 165 potential vaccines against COVID-19. Equally impressive innovations are speeding vaccine testing within a rigorous scientific framework, while manufacturing and transportation capacity are being scaled up to distribute millions of doses of future COVID vaccines to those who need them most.
September 24, 2020 — Science Speaks
COVID Vaccines 101: Breaking Down the Good, the Bad, and the Promise of the Frontrunners
With hundreds of potential COVID vaccine candidates being tested around the world, here’s a quick guide to which ones you should keep an eye on — and when we could see results.
September 17, 2020 — Bhekisisa
Standardized Metrics Can Reveal Region-Specific Opportunities in Community Engagement to Aid Recruitment in HIV Prevention Trials
Standardized metrics and data collection aid meaningful comparisons of optimal community engagement methods for trial enrollment. Internet strategies had better success in the Americas/Switzerland than in sub-Saharan African countries. Data are essential in outreach staff efforts to improve screening-to-enrollment ratios.
September 17, 2020 — PLOS One
South Africa Is ‘Extremely Unlikely’ to Have COVID Vaccine Results Before Next Year
One of South Africa’s three COVID-19 vaccine trials was recently put on hold after a participant in the United Kingdom developed an unexplained illness. After an independent review, AstraZeneca’s candidate, which was considered to be a frontrunner in the field, is expected to resume locally this week. But results are still a long shot for this year, says the trial’s lead investigator.
September 15, 2020 — Bhekisisa
Pharmacies Grapple With Red Tape as States Try to Allow Pharmacists to Prescribe PrEP
The California law allowing pharmacists to prescribe HIV prevention medication has encouraged lawmakers around the country to pass similar measures to reduce hurdles and expand access to pre-exposure prophylaxis (PrEP). With the passage of Senate Bill 159, California became the first state in the nation to allow pharmacists to provide PrEP and post-exposure prophylaxis (PEP).
September 10, 2020 — The BodyPro
Ten Minutes with Maureen Luba, Africa Region Advocacy Advisor at AVAC, Lilongwe, Malawi
Maureen Luba is the Africa Region Advocacy Advisor at AIDS Vaccine Advocacy Coalition (AVAC) where she helps lead capacity building efforts around strategy development, data analytics and use for advocacy for Civil Society Organizations in Zimbabwe, Tanzania and Malawi to effectively engage in Global Fund, PEPFAR and national policy decision-making processes. She graduated from the University of Malawi with a Bachelor’s Degree in Public Administration.
September 10, 2020 — BMJ Leader
AVAC Webinar With Barney Graham: COVID-19 Vacines Targets, Timelines, Efficacy and Ethical Issues
An excellent webinar from AVAC on deleopments in COVID-19 vaccine research is now online featuring a talk by Barney Graham, Director of US NIH Vaccine Research Centre (VRC). The talk reviews the rapid development timeline for COVID-19 vaccines, including the role played by HIV researchers and trial networks, and covers some of the recent research developments.
August 27, 2020 — i-base
A Vaginal Ring to Prevent HIV Was Given a Positive Opinion by a European Drug Regulator. Here’s What You Need to Know About It
On July 24, the European Medicines Agency (EMA) adopted a positive opinion on the dapivirine vaginal ring for use by cisgender women ages 18 and older in developing countries to reduce the risk of HIV. The ring is an important user-controlled option for women who choose not to, or are unable to, use pre-exposure prophylaxis (PrEP).
August 18, 2020 — The BodyPro
AVAC Launches Dynamic Global PrEP Data Tool
Five years into tracking global pre-exposure prophylaxis (PrEP) data, the HIV advocacy organization AVAC has launched a new interactive site that allows users to visualize worldwide country-level information about PrEP use.
August 5, 2020 — POZ
Scientists Are Working to Fast-Forward COVID-19 Research, but Not at the Expense of Ethics
Typically, it can take at least a decade to develop a new vaccine, with the shortest timeline in history being four years to develop one for mumps. As part of this process, potential vaccines go through stages of research, from preclinical work in animals to phase one clinical trials that test the safety of potential vaccines in healthy volunteers. From there, vaccine candidates move onto larger phase two and three studies that see if the vaccines are effective at preventing a given disease.
August 5, 2020 — Bhekisisa
COVID-19 Vaccine Trials Worry US Minority Communities
The US government has stepped up efforts to persuade members of minority communities to participate in clinical trials for COVID-19 vaccines, fearing that their historical suspicion of public health authorities will limit the number of volunteers.
August 4, 2020 — Financial Times
UPDATED: Will People With HIV Be Excluded From COVID-19 Vaccine Trials?
As the world waits with baited breath for a safe and effective vaccine to prevent SARS-CoV-2, the new coronavirus that causes COVID-19, people living with HIV are concerned that they may be excluded from clinical trials testing these vaccines.
July 30, 2020 — POZ
Dapivirine Vaginal Ring Gets Nod for HIV Prevention Among Women
A vaginal ring that has been undergoing trials has been given approval by the European Medicines Agency to be used as an HIV prevention method among women who have tested negative.
July 25, 2020 — The Independent
Decades of Research on an HIV Vaccine Boost the Bid for One Against Coronavirus
In 1984, scientists discovered the virus at the root of an alarming epidemic that was sickening otherwise healthy young men with aggressive cancers and rare, life-threatening pneumonias. Thirty-six years later, there still is no HIV vaccine. But instead of being a cautionary tale of scientific hubris, that unsuccessful effort is leading to even greater confidence in the search for a coronavirus vaccine, from some of the same researchers who have spent their careers seeking a cure for AIDS.
July 14, 2020 — Washington Post
Confronting Missed Targets, HIV/AIDS Experts Emphasize Drug Delivery
The conversation at AIDS 2020 is focusing not just on developing new technologies to fight HIV/AIDS — but also ensuring the tools that already exist realize their potential for impact. As the world falls short of 2020 targets for progress on HIV/AIDS, global health experts are highlighting the need to make testing, prevention, and treatment affordable and accessible.
July 8, 2020 — Devex
This Injection Outperforms a Daily Pill to Prevent HIV Infection. Will You Use It?
An injection every two months is three times more effective in preventing HIV infection among men and transgender women than a daily prevention pill.
July 8, 2020 — Bhekisisa
This Year’s AIDS Conference Has Brought Snippets of Good News
Even in the days of the internet, conferences remain the lifeblood of science. Young thrusters can meet old fogeys and lobby them for jobs. Ideas can be swapped in the knowledge that no electronic trail will come back to haunt you. And journalists can swoop, scoop up a bundle of interesting stories and, with luck, provide an update to their readers and viewers of developments in whatever field the conference was about.
July 8, 2020 — The Economist
Researchers Highlight Importance of Youth, Women in HIV Prevention Research
Researchers discussed HIV prevention research during a press conference at the AIDS 2020 meeting, highlighting the importance of involving young people and women. The event included perspectives from various researchers on successful interventions and disruptions to treatment because of the COVID-19 pandemic.
July 8, 2020 — Healio
New Law Aims to Expand Access to HIV Prevention — But Will It?
Back in March, Quadeer Jones, a 23-year-old actor in Los Angeles, decided to get pre-exposure prophylaxis, or PrEP, to protect himself from HIV when having sex. He made an appointment at the Los Angeles LGBT Center to get PrEP medication, the antiretroviral Truvada, traveling more than 30 miles. Once he arrived at the center, the process was relatively easy. “I had to schedule an appointment for rapid HIV testing,” he says. “They said I was negative. I got my prescription and meds and I was out the door in about an hour.”
July 7, 2020 — Capital & Main
Investigational PrEP Injection, Dosed Every Other Month, Beats Daily PrEP in Phase 3 Study
Taken every 2 months, the long-acting injectable drug cabotegravir (CAB-LA) prevented more HIV infections than daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC), according to newly announced results from a major Phase 3 study. The results were released originally in May due to the overwhelmingly positive data on CAB-LA for PrEP, but researchers presented their final data in early July at the 23rd International AIDS Conference (AIDS 2020).
July 7, 2020 — The BodyPro
Can This New Injectable Deliver on Its Promise to Reduce HIV Transmission?
New clinical evidence shows that cabotegravir, an investigative injectable drug under development for HIV prevention and treatment, is 66 percent more effective than oral preexposure prophylaxis.
July 7, 2020 — Devex
Partnership Science
Mark Feinberg and Helen Rees joined Mitchell Warren for a webinar titled “Pandemic Vaccine Development and Lessons for COVID-19” in April 2020. It is part of the COVID-19 and HIV webinar series hosted by AVAC, which focuses on global advocacy for HIV prevention.
June 29, 2020 — POZ
Easier and Equitable Access to PrEP: How DSD Can Help Get Us There
Improving access to HIV prevention is critical if we want to see meaningful reductions in new infections. Although the adoption and use of oral pre-exposure prophylaxis (PrEP) has gradually increased, with an estimated half a million people initiating PrEP worldwide, we are far from achieving the global target of three million users by the end of 2020.
June 24, 2020 — Differentiated Service Delivery
The Dangers of Excluding Women From HIV Prevention Drug Tests
When Dázon Dixon Diallo began working to prevent the spread of HIV among women in 1985, she first had to convince them that they could get the infection. Even some HIV activists didn’t fully appreciate that women needed to be included in prevention efforts. Diallo founded an Atlanta-based organization called SisterLove to promote reproductive justice and to support women with or at risk of getting HIV/AIDS, expanding it to a program in South Africa, where today two-thirds of the people living with HIV are women. In the US, almost one in five new HIV diagnoses are among women.
June 10, 2020 — Wired
HIV Prevention Clinical Trials’ Community Engagement Guidelines: Inequality, and Ethical Conflicts
We reflect on the events that led to the controversies and identified that scientific and ethical concerns raised by members of local communities at each of these sites were erased by trialists, causing crisis that led to premature shut down the early PrEP trials. In the aftermath of these trials, the World Health Organisation, UNAIDS, and AVAC developed ethics guidelines intended to recognize the concerns as authentic, and developed guidelines to improve researchers’ engagement of communities in biomedical HIV prevention trial design and implementation.
June 5, 2020 — Global Bioethics
Opinion: To Accelerate Search for COVID-19 Vaccine, Look to HIV and Act Globally
In just six months, the virus that causes COVID-19 has spread around the world, infected over 5 million people, and exacted devastating public health and economic tolls that are only just beginning. Unprecedented efforts to accelerate the development of a vaccine for the virus underscore the urgency of this public health crisis.
May 27, 2020 — Devex
HIV Injectable Tx May Work in Men — But What About Women?
While results for the long-acting HIV prevention medication cabotegravir are promising in men who have sex with men (MSM), there is still no data on this drug in women, begging the question of whether this will be another HIV prevention option that ends up being approved for only one population.
May 19, 2020 — MedPage Today
Long-Acting Injectable PrEP Proves Highly Effective
A major clinical trial comparing ViiV Healthcare’s long-acting injectable cabotegravir dosed every eight weeks with daily oral Truvada (tenofovir disoproxil fumarate/emtricitabine) for use as pre-exposure prophylaxis (PrEP) against HIV halted its blinded, placebo-controlled phase early when cabotegravir was found highly effective at preventing acquisition of the virus among transgender women and cisgender men who have sex with men (MSM).
May 18, 2020 — POZ
Investigational PrEP Injection, Dosed Every Other Month, Holds Up Against Daily PrEP in Phase 3 Study
Taken every 2 months, the long-acting injectable drug cabotegravir prevented more HIV infections than daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC), according to newly announced results from a major Phase 3 study.
May 18, 2020 — The BodyPro
COVID-19, Yes but HIV Needs Attention Too
While there is a need for COVID-19 research, it is also important not to erase other important public health issues, such as HIV. Let us not let COVID-19 make us abandon the efforts we have put into HIV research and implementation and stall the progress made this far.
May 18, 2020 — The Times Malawi
HIV Vaccines: Are You Aware?
Today, we honour HIV Vaccine Awareness Day, as we do every May 18. As an HIV prevention advocate, I want to celebrate and thank the Zambian government for hosting the Imbokodo study, one of only two ongoing HIV vaccine efficacy trials on the globe. As a nation, we should also thank the altruistic women who give their bodies, time and hope as trial participants so that this vaccine study might finally lead us on a path to ending HIV transmission.
May 18, 2020 — Zambia Daily Mail
Human Challenge Studies for a COVID-19 Vaccine: Ethical Quandaries
Experts in infectious disease and public health warn that the COVID-19 pandemic will be with us for a long time unless a vaccine becomes available soon, which is not likely. Estimates of how long it will take for an effective vaccine to come to market range from 12 to 18 months or longer. This situation has given rise to calls for human challenge studies. In these types of studies, researchers inject healthy volunteers with an experimental vaccine, after which the participants are infected with a strain of the disease in order to test the vaccine’s efficacy.
May 15, 2020 — The Doctor’s Tablet Blog
Monkey Trials Offer New Hope for HIV Vaccine
An experimental vaccine seems to give monkeys extended protection from an HIV-like infection — by “waking up” an arm of the immune system that vaccines normally do not. Experts cautioned that animal research often does not pan out in humans. The decades of work toward an HIV vaccine has been a clear example. But, researchers said, this vaccine works differently, targeting two “arms” of the immune system.
May 11, 2020 — US News & World Report
HIV Prevention Trials Paused During Coronavirus Crisis
During the COVID-19 crisis, a number of the ongoing worldwide HIV vaccine and immunotherapy efficacy trials are being paused or curtailed.
April 22, 2020 — aidsmap
How COVID-19 Must Transform US Global Health Strategy
While the COVID-19 pandemic is raging in the US, Africa faces the prospect of imminent catastrophe, where at least 300,000 Africans could die from the disease and 29 million people may be pushed into extreme poverty. Viruses do not respect borders, and we know that America will not be safe if COVID-19 is out of control on other continents.
April 21, 2020 — The Hill
Helen Rees: The Prof Leading SA’s COVID-19 Vaccine Trial
If one were to list all the titles and positions held by Prof. Helen Rees, who is leading the SA part of a global trial to identify treatments for COVID-19, there would be no space to write anything else.
April 9, 2020 — finacialmail
Deborah Birx: The US Colonel at War With Coronavirus
The image on the slide deck was stark — a chart in the form of a towering blue mountain that showed the US facing a potential 2.2m deaths from coronavirus, were certain measures not taken. But the voice delivering the message was calm, almost soothing.
April 6, 2020 — Financial Times
COVID-19: The HIV Research Advocacy Movement Offers Lessons
In biomedical research, there is a “before HIV” era, and the world we live in now. Before HIV, most responses to public health crises were dictated top-down by government authorities and medical officials. Research was designed and conducted with little or no community input. Innovation was shunned, collaboration between research institutions avoided, and progress was slow.
April 6, 2020 — Science Speaks
Top HIV Scientist Dies From Coronavirus in ‘Huge Blow’ to the Global Fight Against HIV/AIDS
Professor Gita Ramjee, a highly acclaimed scientist who dedicated her life to fighting and preventing HIV, has sadly died of coronavirus.
April 2, 2020 — Pink News
Deborah Birx, AIDS Researcher, Takes a Prominent Role in Coronavirus Messaging for Trump Administration
When the urgent phone call came last month, respected HIV researcher Deborah Birx was meeting with African officials and activists from around the world at a Johannesburg conference to help determine how US AIDS relief funding would be doled out.
March 25, 2020 — Los Angeles Times
Good News, Bad News in HIV Prevention Research
There was good news and bad news in terms of HIV vaccine and therapeutics research, with several vaccine trials pushing forward even as one came to a premature halt.
March 13, 2020 — MedPage Today
Esnart Sikazindu Advocates HIV Prevention
Esnart Sikazindu’s stint with AVAC as a Fellow in 2020 is a step towards becoming an HIV prevention research advocate.
March 6, 2020 — Zambia Daily Mail
It’s Mad, Mad, Mad, Mad Race
Before we begin the real story, a little bit of fiction. There is a cluster of houses of complex architecture. Unfortunately, they are in a neighbourhood teeming with the dangerous and cunning criminals. The houses are protected by sophisticated security systems to fight off intruders. They have multiple layers of response mechanisms from the moment any intrusion is detected. They are engineered so that they can assess the threat perception and neutralize the intruder through a series of autonomous actions at different levels.
February 22, 2020 — Outlook
We’ll Only Rest Once We Get Vaccine, Say Experts Despite Failed Test
HIV researchers in Kenya and around the world are regrouping to look for a way forward after a promising new vaccine failed a critical test.
February 11, 2020 — Daily Nation
Why We’re Still Optimistic Even in Disappointment About an HIV Vaccine
An HIV vaccine remains what South Africa and the world needs to prevent new HIV infections. This is in addition to a range of other HIV prevention tools that are available and in the pipeline. However, one of the HIV vaccine research studies, Uhambo (HVTN 702), has been stopped early because it was determined by an independent review body that it did not show a possibility to prevent HIV. This, for a moment, came as disappointing news; however, as South Africans we realise the search for a safe and effective HIV vaccine has to continue.
February 6, 2020 — Daily Maverick
Another HIV Vaccine Fails a Trial, Disappointing Researchers
In another setback in the long quest to prevent HIV infection, a trial in South Africa has been shut down because an experimental vaccine was not working, federal health officials announced on Monday.
February 4, 2020 — New York Times
Promising HIV Vaccine Proves Ineffective
A vaccine trial against HIV in South Africa has proven ineffective, prompting the National Institute of Allergy and Infectious Diseases to stop it. Scientists were cautiously optimistic about the trial, which involved 5,407 HIV-negative volunteers at 14 sites across South Africa.
February 4, 2020 — Devex
Large Scale HIV Vaccine Study Failed, but There’s Hope
One of the biggest HIV vaccine trials in the world, the HVTN 702 study, was stopped late on Monday because the vaccine had not been proven effective in preventing HIV. This is according to the United States National Institute of Allergy and Infectious Diseases (NIAID), who are one of the funders of the clinical trial.
February 4, 2020 — Health-E News
Another HIV Vaccine Strategy Fails in Large-scale Study
The HIV vaccine that had moved furthest along in human testing does not work, and the $104 million trial in South Africa evaluating it has been stopped early.
February 3, 2020 — Science
Trial of Promising HIV Vaccine Halted After Failing to Show Benefit
A clinical trial testing a promising HIV vaccine in more than 5,000 people in South Africa has been halted because it failed to show a benefit, US health officials said on Monday.
February 3, 2020 — Reuters
‘Incredibly Disappointing’: Fred Hutch, Feds End HIV Vaccine Trial After Data Shows No Benefit
In another blow to the decades-long quest for an HIV vaccine, researchers are pulling the plug on the largest ongoing clinical trial after a review in January found the experimental injections provided no protection from the virus that causes AIDS.
February 3, 2020 — Seattle Times
HIV Vaccine Trial Stopped After Jab Found Ineffective
Suth Africa will halt one of the largest and most advanced HIV vaccine trials ever to be undertaken in the country ahead of schedule after the jab was found to be safe but not effective at protecting against HIV infection.
February 3, 2020 — Bhekisisa
The Global Gag Rule Is Still Hurting Women and Girls
The US Government knows how to do smart, effective HIV programming globally — but for the past three years, it has been getting in its own way. That’s because the US President’s Emergency Plan for AIDS Relief (PEPFAR), the largest government commitment to global HIV, was placed at risk when President Trump reintroduced the so-called global gag rule, applying it for the first time to PEPFAR.
January 23, 2020 — INKSTICK
In Search of Comprehensive HIV Prevention
A nightclub at Balaka Town is bulging with sex workers and their clients in search of pleasure and money. Within the compound, faint lights from florescent tubes are casting small beams onto an entrance into an adjoining room.
January 13, 2020 — The Times Malawi
Partners Must Prioritize Access in Fight Against HIV/AIDS, Experts Say
Over the past 30 years, advances ranging from medical technology to policy implementation have reduced new infections and suppressed the virus for those already living with HIV. There is a lot of excitement about technological innovations already on the market and those that will be available in the near future, including preexposure prophylaxis, or PrEP, which could soon be available as implants instead of daily pills. But progress in the global fight against HIV has been uneven, with the San Francisco Bay Area serving as an example of the global inequities in the disease burden.
January 9, 2020 — Devex
→ Continue through the archives. Find articles from 2019 and older.